Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients.

Author(s): Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME

Affiliation(s): Department of Nephrology, Dicle University Medical Faculty, Diyarbakir, Turkey. drdede75@hotmail.com

Publication date & source: 2007-03, Adv Ther., 24(2):387-93.

Publication type: Randomized Controlled Trial

This study was undertaken to evaluate the effectiveness of prophylactic intranasal mupirocin for peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD). A total of 49 patients undergoing CAPD for at least 6 mo were followed for 1 year. A nasal smear was obtained from each patient at the beginning and end of the study. Intranasal mupirocin ointment was administered to the nares twice daily for 5 d every 4 wk in the mupirocin group. The frequency of Staphylococcus aureus nasal carriage was similar in both groups at the beginning, and S aureus was eradicated in 56.5% of patients in the mupirocin group; 29% of patients in the control group had negative nasal smear culture findings at the end of the study. Peritonitis episodes occurred at rates of 4.3% in the mupirocin group and 4.1% in the control group (P>.05). Prophylactic administration of intranasal mupirocin ointment was ineffective in reducing episodes of peritonitis.